Professor | Liguang Lou | Asia Growth Partners

Name

Liguang Lou

Contact Information

lglou@mail.shcnc.ac.cn

Language ability

English, Chinese

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2000-03--2002-06 Postdoctoral: University of Pittsburgh, USA 1996-09--1998-07 Postdoctoral: Institute of Cell Biology, Chinese Academy of Sciences 1993-09--1996-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences 1990-10--1993-07 Master's: Henan Medical University 1982-09--1985-07 Medical Degree: Zhejiang Jinhua Health School
Work Experience	1998-08--Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher, Researcher 1985-08--1990-07 - Zhejiang Quzhou Health School - Instructor
Awards	National Excellent Postdoctoral Award, First Prize, National, 2005 Meiji Dairy Life Science Award, First Prize, Institute Level, 1998 Guoshi Postdoctoral Award Fund, First Prize, National, 1998 Shanghai Excellent Postdoctoral Award, First Prize, Provincial, 1998

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2000-03--2002-06 Postdoctoral: University of Pittsburgh, USA
1996-09--1998-07 Postdoctoral: Institute of Cell Biology, Chinese Academy of Sciences
1993-09--1996-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1990-10--1993-07 Master's: Henan Medical University
1982-09--1985-07 Medical Degree: Zhejiang Jinhua Health School

Work Experience

1998-08--Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher, Researcher
1985-08--1990-07 - Zhejiang Quzhou Health School - Instructor

Awards

Areas of Focus	Tumor Pharmacology Antitumor Drug Discovery and Development
Publications	Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug Resistance., Liguang Lou, 2024 SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs., Liguang Lou, 2024 Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors., Dong, Qian, Tong, Mengya, Yu, Xiaolu, Wang, Lei, Ao, Jiwei, Guan, Dongliang, Tang, Yubo, Liu, Junjie, Long, Li, Tong, Yongliang, Fang, Shanhua, Zhou, Hu, Huang, Yongzhuo, Gong, Likun, Lou, Liguang, Huang, Wei, 2023 Modular Biomimetic Strategy Enabled Discovery of Simplified Pseudo-Natural Macrocyclic P-Glycoprotein Inhibitors Capable of Overcoming Multidrug Resistance., Liu, Bo, Yu, Xueni, Liu, Liping, Wang, Lei, Wang, Jie, Huang, Qianqian, Xu, Zhongliang, Luo, Cheng, Lou, Liguang, Huang, Wei, Yang, Weibo, 2023 Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers., Li, Yongpeng, Li, Lin, Fu, Haoyu, Yao, Qing, Wang, Lei, Lou, Liguang, 2023

Areas of Focus

Tumor Pharmacology
Antitumor Drug Discovery and Development

Publications

Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug Resistance., Liguang Lou, 2024
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs., Liguang Lou, 2024
Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors., Dong, Qian, Tong, Mengya, Yu, Xiaolu, Wang, Lei, Ao, Jiwei, Guan, Dongliang, Tang, Yubo, Liu, Junjie, Long, Li, Tong, Yongliang, Fang, Shanhua, Zhou, Hu, Huang, Yongzhuo, Gong, Likun, Lou, Liguang, Huang, Wei, 2023
Modular Biomimetic Strategy Enabled Discovery of Simplified Pseudo-Natural Macrocyclic P-Glycoprotein Inhibitors Capable of Overcoming Multidrug Resistance., Liu, Bo, Yu, Xueni, Liu, Liping, Wang, Lei, Wang, Jie, Huang, Qianqian, Xu, Zhongliang, Luo, Cheng, Lou, Liguang, Huang, Wei, Yang, Weibo, 2023
Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers., Li, Yongpeng, Li, Lin, Fu, Haoyu, Yao, Qing, Wang, Lei, Lou, Liguang, 2023

Cancer Pharmacology Drug Discovery Antitumor Research Development Chemotherapy Biotechnology Clinical Trials Molecular Biology

Yuliang Feng - Southern University of Science and Technology

Jialing Liu - Southern University of Science and Technology

Peng Tan - Southern University of Science and Technology

View All

Personal Information